The present disclosure relates the combined effect of anti-CD155 [CD155, Nectin-like protein 5 (Nec1-5), Tage4, HVED, poliovirus receptor (PVR)] antibodies or anti TIGIT antibodies [TIGIT (T cell immunoreceptor with Ig and ITIM domains), WUCAM (Washington University cell adhesion molecule), Vstm3 (V-set and transmembrane domaincontaining protein 3), Vsig9 (V-set and immunoglobulin domain-containing protein 9)] with a TGF Beta 1 antagonist. The effect is measured by increased IFN-gamma production human breast adenocarcinoma cells. Use of combined antibodies /CD155 or TIGIT) with a TGF-Beta 1 antagon-ist to treat a patient with cancer is claimed.
